Current status of immunisation for herpes zoster

被引：2

作者：

Cunningham, Anthony Lawrence ^{[1
,2
]}

Sandgren, Kerrie Jane ^{[1
,2
]}

Taylor, Janette ^{[1
,3
]}

机构：

[1] Westmead Inst Med Res, Ctr Virus Res, 176 Hawkesbury Rd, Westmead, NSW 2145, Australia

[2] Univ Sydney, Fac Med & Hlth, Sydney Inst Infect Dis Sydney ID, Sydney, NSW, Australia

[3] Westmead Hosp, Ctr Infect Dis & Microbiol Lab Serv, Westmead, NSW, Australia

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2025年 / 21卷 / 01期

基金：

英国医学研究理事会;

关键词：

Herpes zoster; recombinant zoster vaccine; adjuvant; protein vaccine; aging; immune-compromised; vaccine efficacy; vaccine durability; vaccine reactogenicity; SUBUNIT CANDIDATE VACCINE; ADULTS GREATER-THAN-OR-EQUAL-TO-50 YEARS; OLDER-ADULTS; AGED; 50; IMMUNOGENICITY; SAFETY; VIRUS; EFFICACY;

D O I：

10.1080/21645515.2024.2445384

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Herpes zoster (HZ) is increasingly common in the aging and is experienced by approximately one in three people in their lifetime. It is also relatively common in immune-compromised people. Acute HZ causes severe pain, reduced quality of life and severe complications, including prolonged pain, or postherpetic neuralgia (PHN), and ocular zoster, which may rarely progress to blindness. In severely immune-compromised people disseminated zoster may affect the brain and liver. A second-generation vaccine, the Recombinant Zoster Vaccine, consisting of recombinant viral glycoprotein E and the Adjuvant System 01 (AS01B), now offers >90% efficacy against HZ and associated complications in immune-competent people. Efficacy persists above 80% for 11 years. In severely immune-compromised patients, the vaccine is safe with efficacy and/or immunogenicity of 68-87%. There is also excellent immunogenicity for those on JAK inhibitors and corticosteroid therapy. The vaccine offers a paradigm for successful and durable immunization in the aging and immune-compromised.

引用

页数：8

共 62 条

[1]

[Anonymous], 2024, Department of health and aged care, Australian government

[2] Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation A Randomized Clinical Trial [J].

Bastidas, Adriana ;

de la Serna, Javier ;

El Idrissi, Mohamed ;

Oostvogels, Lidia ;

Quittet, Philippe ;

Lopez-Jimenez, Javier ;

Vural, Filiz ;

Pohlreich, David ;

Zuckerman, Tsila ;

Issa, Nicolas C. ;

Gaidano, Gianluca ;

Lee, Je-Jung ;

Abhyankar, Sunil ;

Solano, Carlos ;

Perez de Oteyza, Jaime ;

Satlin, Michael J. ;

Schwartz, Stefan ;

Campins, Magda ;

Rocci, Alberto ;

Llamas, Carlos Vallejo ;

Lee, Dong-Gun ;

Tan, Sen Mui ;

Johnston, Anna M. ;

Grigg, Andrew ;

Boeckh, Michael J. ;

Campora, Laura ;

Lopez-Fauqued, Marta ;

Heineman, Thomas C. ;

Stadtmauer, Edward A. ;

Sullivan, Keith M. ;

Alonso Alonso, Aranzazu ;

Anagnostopoulos, Achilles ;

Andreadis, Charalambos ;

Angelopoulou, Maria ;

Anttila, Veli-Jukka ;

Aoun, Mickael ;

Barista, Ibrahim ;

Berkahn, Leanne ;

Bloor, Adrian J. C. ;

Broady, Raewyn ;

Brossart, Peter ;

Buadi, Francis K. ;

Bulabois, Claude-Eric ;

Cantin, Guy ;

Cellini, Claudia ;

Chandrasekar, Pranatharthi Haran ;

Chauncey, Thomas ;

Cuneo, Antonio ;

Dadwal, Sanjeet Singh ;

Dickinson, Michael .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (02) :123-133

[3] Long-Term Effectiveness of the Live Zoster Vaccine in Preventing Shingles: A Cohort Study [J].

Baxter, Roger ;

Bartlett, Joan ;

Fireman, Bruce ;

Marks, Morgan ;

Hansen, John ;

Lewis, Edwin ;

Aukes, Laurie ;

Chen, Yong ;

Klein, Nicola P. ;

Saddier, Patricia .

AMERICAN JOURNAL OF EPIDEMIOLOGY, 2018, 187 (01) :161-169

[4]

BERGEN R E, 1991, Viral Immunology, V4, P151, DOI 10.1089/vim.1991.4.151

[5] Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study [J].

Berkowitz, Elchonon M. ;

Moyle, Graeme ;

Stellbrink, Hans-Juergen ;

Schuermann, Dirk ;

Kegg, Stephen ;

Stoll, Matthias ;

El Idrissi, Mohamed ;

Oostvogels, Lidia ;

Heineman, Thomas C. .

JOURNAL OF INFECTIOUS DISEASES, 2015, 211 (08) :1279-1287

[6] The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70 [J].

Boutry, Celine ;

Hastie, Andrew ;

Diez-Domingo, Javier ;

Tinoco, Juan Carlos ;

Yu, Chong-Jen ;

Andrews, Charles ;

Beytout, Jean ;

Caso, Covadonga ;

Cheng, Huey-Shinn ;

Cheong, Hee Jin ;

Choo, Eun Ju ;

Curiac, Dan ;

Di Paolo, Emmanuel ;

Dionne, Marc ;

Eckermann, Tamara ;

Esen, Meral ;

Ferguson, Murdo ;

Ghesquiere, Wayne ;

Hwang, Shinn-Jang ;

Avelino-Silva, Thiago Junqueira ;

Kosina, Pavel ;

Liu, Chiu-Shong ;

Markkula, Jukka ;

Moeckesch, Beate ;

de Oliveira, Claudia Murta ;

Park, Dae Won ;

Pauksens, Karlis ;

Pirrotta, Paola ;

Plassmann, Georg ;

Pretswell, Carol ;

Rombo, Lars ;

Salaun, Bruno ;

Berglund, Johan Sanmartin ;

Schenkenberger, Isabelle ;

Schwarz, Tino ;

Shi, Meng ;

Ukkonen, Benita ;

Zahaf, Toufik ;

Zerbini, Cristiano ;

Schuind, Anne ;

Cunningham, Anthony L. .

CLINICAL INFECTIOUS DISEASES, 2022, 74 (08) :1459-1467

[7] Association Between Immunogenicity and Reactogenicity: A Post Hoc Analysis of 2 Phase 3 Studies With the Adjuvanted Recombinant Zoster Vaccine [J].

Callegaro, Andrea ;

Burny, Wivine ;

Herve, Caroline ;

Kim, Joon Hyung ;

Levin, Myron J. ;

Zahaf, Toufik ;

Cunningham, Anthony L. ;

Didierlaurent, Arnaud M. .

JOURNAL OF INFECTIOUS DISEASES, 2022, 226 (11) :1943-1948

[8]

Centres for Disease Control and Prevention (CDC), 2022, Clinical considerations for use of recombinant zoster vaccine (RZV, shingrix) in immunocompromised adults aged ≥19 years

[9] Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: A phase II, randomized, controlled study [J].